In the editorial for the May issue of Vascular Disease Management, editor in chief Frank J. Criado, MD, FACS, FSVM, reflects on important topics discussed at the 35th annual Charing Cross symposium. One topic he reports hearing about often is type II endoleaks.
“Although there is not much ‘new’ to report, I did come out with the distinct impression that management guidelines and outcome implications of type II endoleaks may not be as clear as I thought they had become in recent years,” writes Dr. Criado. “Several noted experts in the EVAR field expressed reasoned doubt about the prevailing view that ‘type II endoleaks are benign,’ advancing the concept that such endoleaks may well carry significant long-term potential for AAA complications and the need for reinterventions.”
The future will bring changes to the approach to type II endoleaks, says Dr. Criado, especially given the potential release of the Endologix Nellix “aneurysm sealing system” in the US, which could nearly eliminate type II endoleaks.
Dr. Criado also addressed the Nellix device in the Vascular Access blog, noting that it received CE Mark in September: “The Nellix system is truly revolutionary in its conception and design, treating aneurysms by filling or sealing the sac, as opposed to anchoring and sealing at the proximal neck, which has been at the center of EVAR therapy from its inception.”
Related content: “AAA Repair: When Will EVAR Become the Gold Standard?“